Waters Corporation
NYSE•WAT
CEO: Dr. Udit Batra Ph.D.
セクター: Healthcare
業種: Medical - Diagnostics & Research
上場日: 1995-11-17
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.
連絡先情報
時価総額
$18.78B
PER (TTM)
29.2
31.5
配当利回り
--
52週高値
$414.15
52週安値
$275.05
52週レンジ
順位27Top 14.4%
5.4
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.4 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$932.36M+0.00%
直近4四半期の推移
EPS
$3.78+0.00%
直近4四半期の推移
フリーCF
$125.58M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Total Net Sales Increase Total net sales reached $3.17B USD in 2025, marking a 7% increase driven by strong customer demand across major geographies.
Chemistry Consumables Growth Chemistry consumables sales grew 12% to $631.5M USD in 2025, supported by uptake in columns and pharmaceutical testing kits.
Transformative BDS Acquisition Completed $16.8B USD acquisition of BD Biosciences & Diagnostic Solutions in February 2026, establishing a global life sciences leader.
Net Income Remained Stable Net income was $642.6M USD in 2025, showing a 1% increase despite operating income declining 3% from prior year.
リスク要因
BDS Integration Challenges Failure to integrate BDS Business within expected timeline could adversely affect future results and realization of anticipated synergies.
Foreign Currency Fluctuation Risk International operations face negative impact from foreign currency fluctuations, affecting translation of non-U.S. operating results.
Customer Demand Changes Financial results subject to changes in customer demand, especially pharmaceutical spending, which may decrease beyond Company control.
Competitive Technology Disruption Competitors may introduce more effective or less expensive products, potentially decreasing sales and harming market position.
見通し
Increased R&D Investment R&D expenses increased 7% in 2025 to $195.7M USD, reflecting commitment to new product development and technology initiatives.
New Four Segment Structure Reorganized business into four segments post-BDS acquisition: Analytical, Biosciences, Advanced Diagnostics, and Materials Sciences.
Realizing Acquisition Synergies Expect cost synergies of $200M USD within three years and revenue synergies of $290M USD within five years post-BDS close.
Share Repurchase Authorization Board authorized share repurchase extension through January 2028, maintaining $1.0B remaining authorization capacity.
同業比較
売上高 (TTM)
$13.95B
$11.04B
$9.81B
粗利益率 (最新四半期)
92.3%
90.9%
86.9%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| BIIB | $27.60B | 21.3 | 7.3% | 23.6% |
| DXCM | $27.57B | 32.7 | 32.4% | 21.9% |
| MTD | $25.76B | 29.6 | -487.2% | 63.1% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
12.1%
安定成長
4四半期純利益CAGR
22.9%
収益性の大幅な改善
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年5月4日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし